Enterprise Value to EBITDA Ratio: Citius Oncology, Inc. (CTOR)
Citius Oncology, Inc. (CTOR) is developing anti-tumor methods through alliances with biotech giants to bring drugs to market. The business relies on collaboration with medical centers to implement targeted therapy for lymphomas. The company is currently preparing to launch a specialized treatment for T-cell skin lesions. The EV/EBITDA metric stands at 0.00, which is clearly demonstrated by the price chart on the GURU.Markets platform.
Summary analytical data breakdowns for citiusonc.com (CTOR)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Citius Oncology, Inc.|CTOR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Citius Oncology|CTOR - Company Total Debt Obligations|Debt to Book Value Citius Oncology Inc|CTOR - Amount of Long-Term Liabilities|Company Short-Term Debts Citius Oncology|Quick Liquidity Indicator citiusonc.com
- business earnings and investment ratios data:
CTOR - Net Profit|Expected Profit Citius Oncology, Inc.|CTOR - Business Payback Period|Projected Price to Earnings Citius Oncology, Inc.|CTOR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology Inc|CTOR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Citius Oncology|CTOR - Earnings per share for the last 12 months|Quarterly EPS earnings growth citiusonc.com|CTOR - Net earnings per share growth this year|Net earnings per share growth forecast for next year Citius Oncology, Inc.
Comprehensive company analysis:Citius Oncology, Inc (CTOR)
This indicator compares the total enterprise value, including debt, with its earnings before interest, taxes, depreciation, and amortization. The metric allows for an objective valuation of capital-intensive assets by excluding the influence of financing structures. The EV/EBITDA ratio dynamics for the company, accounting for debt load, reflect market expectations regarding resource management efficiency. For Citius Oncology, Inc. (CTOR), this is critically important when scaling sales of the drug LYMPHIR and expanding insurance coverage.
Competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to EBITDA Ratio delcath.com DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Aura Biosciences Inc (AURA)|CADL: Enterprise Value to EBITDA Ratio|Accuray, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SLS: EV/EBITDA Multiple|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio HURA|EV/EBITDA Multiple Protara Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fate Therapeutics Corp (FATE)|Total Company Value to Operating Income Before Depreciation Ratio aadibio.com|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA CEL-SCI Corporation|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RADX|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Adlai Nortye Limited (ANL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Renovaro Biosciences - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Kairos Pharma Ltd|OKUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple CytoMed Therapeutics Limited GDTC|Enterprise Value to EBITDA Ratio CRIS|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (advanbiomed.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to EBITDA Ratio AONC|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|iCAD - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio IKNA (Ikena Oncology Inc.)|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Viracta Therapeutics|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
